Welcome to our dedicated page for Conmed SEC filings (Ticker: CNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CONMED Corporation filings document the regulatory record for a medical technology company with common stock listed on the NYSE under the symbol CNMD. Its Form 8-K reports cover quarterly and annual operating results, investor presentations furnished under Regulation FD, finance leadership changes, and portfolio actions involving gastroenterology products and distribution agreements.
The company’s proxy materials disclose board matters, annual meeting voting, executive compensation, equity awards, and related governance information. CONMED’s filing record also identifies its capital stock structure, including common stock with $0.01 par value, and provides formal exhibits for earnings releases, presentations, transition agreements, and other material corporate updates.
CONMED Corp (CNMD) insider transaction: Executive Vice President & CFO Todd W. Garner reported RSU-related activity on 10/31/2025. He acquired 7,500 shares of common stock at $0 upon settlement of restricted stock units (transaction code M), then had 2,164 shares withheld at $44 per share for taxes (code F).
After these transactions, he holds 5,336 shares directly. He also reports 15,227 RSUs as derivative securities beneficially owned following the transactions. Each RSU represents a right to receive one share of common stock. The RSUs are under the Company’s 2018 Long‑Term Incentive Plan, vesting over two years with 33% after year 1 and 67% after year 2.
CONMED Corp (CNMD) director Charles Farkas reported two open-market sales totaling 2,000 shares on 09/12/2025. The filings show a sale of 1,103 shares at $53.535 and a sale of 897 shares at $53.512. The beneficial ownership reported after the transactions is shown as 15,756 shares and 14,859 shares on the respective lines. The Form 4 is signed by Thomas Fistek on behalf of Mr. Farkas by power of attorney on 09/15/2025.
CONMED Corp (CNMD) director Charles Farkas reported two open-market sales totaling 2,000 shares on 09/12/2025. The filings show a sale of 1,103 shares at $53.535 and a sale of 897 shares at $53.512. The beneficial ownership reported after the transactions is shown as 15,756 shares and 14,859 shares on the respective lines. The Form 4 is signed by Thomas Fistek on behalf of Mr. Farkas by power of attorney on 09/15/2025.
CONMED Corp (CNMD) Form 144 notice: The filer intends to sell 2,000 common shares through Fidelity Brokerage Services (Smithfield, RI) on or about 09/12/2025. The filing reports an aggregate market value of $107,049.37 and total shares outstanding of 30,954,963. The 2,000 shares were acquired from the issuer as compensation: 897 shares vested 06/01/2020, 335 vested 06/01/2023, 302 vested 05/31/2024, and 466 received via stock appreciation right on 09/06/2024. No sales by the reporting person in the past three months are reported. The filer signs the required representation that they are unaware of any undisclosed material adverse information about the issuer.
Kim Kelderman, a director of CONMED Corporation (CNMD), was granted equity awards on 09/08/2025 consisting of 500 restricted stock units (RSUs) and options to purchase 6,227 shares of common stock. The RSUs represent the right to receive one share each and generally vest 100% after one year. The stock options have an exercise price of $53.83, vest 100% one year from the grant date, are exercisable beginning 09/08/2026 and expire 09/08/2035.
Following the reported grants, the filing shows beneficial ownership of 500 shares underlying RSUs and 6,227 option shares, held in a direct capacity. The Form 4 was signed on 09/09/2025 by a power of attorney on behalf of the reporting person.
CONMED Corporation appointed Kim Kelderman to its Board of Directors effective September 8, 2025. He will serve on the Corporate Governance and Nominating Committee and the Strategy Committee, and the Board determined that he meets the independence requirements of the New York Stock Exchange and the company’s own standards.
Kelderman is currently President, Chief Executive Officer, and a director of Bio‑Techne, and previously held senior leadership roles at Thermo Fisher Scientific and Becton Dickinson. As a non‑employee director, he will receive the same annual cash and equity compensation as other non‑employee directors. Upon appointment, he received a prorated equity grant valued at approximately $134,766, consisting of 500 restricted stock units and stock options to purchase 6,227 shares of CONMED common stock at the September 8, 2025 closing price, vesting in full on September 8, 2026.
CONMED Corporation filed a Form 3 reporting that Kim Kelderman became a director on 09/08/2025. The filing shows 0 shares of common stock beneficially owned as of the event date and lists the reporting relationship as Director. The Form 3 was executed by power of attorney on 09/09/2025. This is an initial Section 16 filing required when an insider becomes a director; it discloses current ownership (none reported) and does not list any derivative holdings or other indirect ownership.
Fuller & Thaler Asset Management, Inc. filed a Schedule 13G reporting beneficial ownership of 1,740,630.07 shares of Conmed Corp common stock, representing 5.63% of the class. The filer reports sole voting power for 1,714,377.07 shares and sole dispositive power for 1,740,630.07 shares, with no shared voting or dispositive power disclosed.
The filing states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. Fuller & Thaler acts as investment adviser to the underlying accounts that own the shares.
Todd W. Garner, Executive Vice President & CFO of CONMED Corp (CNMD), reported a single insider sale. On 08/07/2025 he sold 598 shares of CONMED common stock at $52.45 per share, and the Form 4 reports he beneficially owns 0 shares following the transaction. The Form 4 was signed via power of attorney on 08/08/2025.
CONMED Corporation announced its Board declared a quarterly cash dividend of $0.20 per share. The dividend was declared on August 7, 2025 and is payable on October 3, 2025 to shareholders of record as of September 15, 2025. This is a cash distribution to owners of the company and represents a direct return of capital to shareholders for the quarter.
The current 8-K contains only the dividend declaration and payment details; it does not disclose earnings, changes to dividend policy, or other financial metrics. Investors seeking additional context on the company’s payout history or cash position will need to consult recent periodic reports or investor presentations.